The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

December 31, 2015

Conditions
Non-Hodgkin's Lymphomas
Interventions
DRUG

Everolimus and rituximab

One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.

Trial Locations (5)

44035

Service Hématologie - Hôtel Dieu de NANTES, Nantes

59037

Service des Maladies du Sang - CHRU de Lille, Lille

69495

Service Hématologie - CHU Lyon Sud, Pierre-Bénite

76038

Service Hématologie - Centre Henri Becquerel, Rouen

94805

Service Hématologie - Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

The Lymphoma Academic Research Organisation

OTHER

NCT01567475 - The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas | Biotech Hunter | Biotech Hunter